Superworth

Johnson & Johnson forward PE JNJ

Share price divided by analysts' consensus earnings for the next twelve months, since 1996.

Today, Nov 3, 2026
23.9×
10-year median
17.1×
Against its 10-year history
99th
percentile: 0 is its lowest day, 100 its highest
10-year range
14.0× to 25.2×
Peer median
18.3×

Johnson & Johnson's forward PE is 23.9× as of Nov 3, 2026.

That is above its ten-year median of 17.1×, higher than on 99% of days in the last ten years.

Over that time it ranged from 14.0× in Jan 2025 to 25.2× in Sep 2026.

The median for 7 large drugmakers of a similar size is 18.3×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far24.0×19.4×25.2×
202519.7×14.0×20.1×
202414.5×14.4×17.5×
202315.9×14.8×18.3×
202217.9×16.3×18.7×
202117.6×16.4×18.7×
202017.9×15.6×20.8×
201919.8×15.2×19.9×
201815.1×14.9×18.9×
201717.9×16.0×18.6×
201616.6×15.1×18.4×
201516.0×14.8×18.1×
201418.1×16.1×18.9×
201317.0×14.1×17.8×
201213.7×12.4×14.1×
201113.4×12.2×13.8×
201013.0×12.3×14.1×
200914.0×11.2×14.3×
200813.8×13.2×17.0×
200716.5×15.1×16.7×

Against its peers

Companies in Drug Manufacturers - General nearest Johnson & Johnson's size, closest first, today.

CompanyForward PE
JNJJohnson & Johnson23.9×
ABBVAbbVie18.3×
MRKMerck17.2×
LLYEli Lilly and30.9×
AMGNAmgen19.8×
GILDGilead Sciences19.8×
PFEPfizer11.2×
BMYBristol-Myers Squibb9.8×
Peer median18.3×

Where Johnson & Johnson ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Johnson & Johnson

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.